Advertisement
Product › Details
Xdivane™
Status | 2020-12-31 development pp existent | |
Organisation | Xbrane Biopharma AB (Nasdaq Stockholm: XBRANE) | |
Group | Xbrane (Group) | |
Record changed: 2023-07-10 |
Advertisement
More documents for nivolumab
- [1] Bavarian Nordic A/S. (7/11/18). "Press Release: Bavarian Nordic Announces Initiation of Phase 2 Trial Evaluating the Combination Therapy of CV301 and Nivolumab in Metastatic Colorectal Cancer". Copenhagen....
- [2] Bavarian Nordic A/S. (3/8/18). "Press Release: Bavarian Nordic Announces Phase 2 Trial Investigating Combination of Its Immunotherapy CV301 and Nivolumab in Microsatellite Stable Colorectal Cancer". Copenhagen....
- [3] Agilent Technologies Inc.. (9/19/17). "Press Release: Agilent Announces Expanded Use of Cancer Diagnostic in the United States. Dako PD-L1 IHC 28-8 PharmDx Approved for Two New Indications". Santa Clara, CA....
- [4] Agilent Technologies Inc.. (6/16/17). "Press Release: Agilent Technologies Announces Expanded Use of Cancer Diagnostic in Europe". Santa Clara, CA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top